

COPY OF PAPERS  
ORIGINALLY FILEDAttorney Docket P1093P1  
Patent Docket P1093P1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of           Manuel Baca et al.           Serial No.: 08/908,469           Filed: August 6, 1997           For: ANTI-VEGF ANTIBODIES</p>	<p>Group Art Unit: 1642           Examiner: Larry R. Helms</p>	<p>RECEIVED MAY 28 2002 TECH CENTER 1600/2900</p>
<p><b>CERTIFICATE OF MAILING</b>          I hereby certify that this correspondence is being deposited with the          United States Postal Service with sufficient postage as first class mail          in an envelope addressed to: Assistant Commissioner of Patents,          Washington, D.C. 20231 on  <i>(Signature)</i>          May 8, 2002  <i>Eileen Ly</i></p>		

## DECLARATION UNDER 37 C.F.R. §1.132

Assistant Commissioner of Patents  
 Washington, D.C. 20231

Sir:

I, Leonard G. Presta, do hereby declare and say as follows:

1. I am currently employed as the Director of Protein and Antibody Technology at DNAX, Palo Alto, California.

2. I am a co-inventor of the above identified application, as are Manuel Baca, James A. Wells, Henry B. Lowman and Yvonne Chen. At the time the application was filed, I was employed as a Staff Scientist in the Department of Immunology at Genentech, Inc., South San Francisco, California, the Assignee of the above-identified application.

3. I am also a co-author of the publication by Manuel Baca, Leonard G. Presta, Shane J. O'Connor and James A. Wells (1997) J. Biol. Chem. 272:10678-10684 (published April 18, 1997), entitled "Antibody Humanization Using Monovalent Phage Display" (hereinafter the "Baca et al. publication").

Attorney Docket P1093P1

4. The subject matter described in the Baca et al. publication is substantially the same as the disclosure in the above-identified patent application, particularly in Example 2 (pages 59-67 of the specification) regarding humanizing the murine anti-VEGF antibody A4.6.1 by randomizing a small set of framework residues and by monovalent display of the resultant library of antibody molecules on the surface of filamentous phage in order to identify high affinity framework sequences via affinity-based selection.

5. Shane J. O'Connor is a co-author on the Baca et al. publication.

6. It is my belief that the subject matter in the Baca et al. publication was derived and produced solely by the conception and design of myself and the co-inventors of the above-identified application.

7. Shane J. O'Connor was a Research Assistant employed at Genentech, reporting directly to me. Shane J. O'Connor carried out some of the experiments reported in the Baca et al. publication under the direct supervision, control and direction of myself and or the other co-inventors of the above-identified application. Shane J. O'Connor provided only manual assistance in implementing the concepts and experimental designs by myself and or the other co-inventors.

8. I hereby declare that all statements made herein of my own knowledge and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application or any patent issued thereon.

By: Leonard G. Presta

Leonard G. Presta

Dated: May 8, 2002